Acadia Healthcare Company Inc vs Crispr Therapeutics AG — how do they compare? Acadia Healthcare Company Inc trades at $31.18 (market cap $2.90B), while Crispr Therapeutics AG trades at $53.88 (market cap $5.23B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and Acadia Healthcare Company Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| ACHC | CRSP | |
|---|---|---|
Market Cap | $2.90B | $5.23B |
Sector | Health | Health |
52-Week High | $35.61 | $76.78 |
52-Week Low | $11.68 | $44.34 |
Enterprise Value | $5.29B | $3.65B |
Trailing returns across standard periods
Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.
Read more on ACHC →CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →